ATE224702T1 - Nichtpolymere verabreichungssysteme mit verzögerter freisetzung - Google Patents

Nichtpolymere verabreichungssysteme mit verzögerter freisetzung

Info

Publication number
ATE224702T1
ATE224702T1 AT96939495T AT96939495T ATE224702T1 AT E224702 T1 ATE224702 T1 AT E224702T1 AT 96939495 T AT96939495 T AT 96939495T AT 96939495 T AT96939495 T AT 96939495T AT E224702 T1 ATE224702 T1 AT E224702T1
Authority
AT
Austria
Prior art keywords
delivery systems
nonpolymeric
sustained release
release delivery
composition
Prior art date
Application number
AT96939495T
Other languages
English (en)
Inventor
Richard L Dunn
Original Assignee
Atrix Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atrix Lab Inc filed Critical Atrix Lab Inc
Application granted granted Critical
Publication of ATE224702T1 publication Critical patent/ATE224702T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Refuse Collection And Transfer (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
AT96939495T 1995-10-27 1996-10-25 Nichtpolymere verabreichungssysteme mit verzögerter freisetzung ATE224702T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/549,414 US5736152A (en) 1995-10-27 1995-10-27 Non-polymeric sustained release delivery system
PCT/US1996/017082 WO1997015285A1 (en) 1995-10-27 1996-10-25 Non-polymeric sustained release delivery system

Publications (1)

Publication Number Publication Date
ATE224702T1 true ATE224702T1 (de) 2002-10-15

Family

ID=24192944

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96939495T ATE224702T1 (de) 1995-10-27 1996-10-25 Nichtpolymere verabreichungssysteme mit verzögerter freisetzung

Country Status (10)

Country Link
US (3) US5736152A (de)
EP (1) EP0862416B1 (de)
JP (2) JP4599498B2 (de)
AT (1) ATE224702T1 (de)
AU (1) AU703365B2 (de)
CA (1) CA2235919C (de)
DE (1) DE69623981T2 (de)
DK (1) DK0862416T3 (de)
ES (1) ES2184895T3 (de)
WO (1) WO1997015285A1 (de)

Families Citing this family (605)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
IL118235A0 (en) * 1996-05-13 1996-09-12 Univ Ben Gurion Composition and method for forming biodegradable implants in situ and uses of these implants
ES2256898T3 (es) * 1996-12-20 2006-07-16 Alza Corporation Composicion de gel y procedimientos.
US6713527B2 (en) * 1997-02-07 2004-03-30 Queen's University At Kingston Anaesthetic bone cement
US6630168B1 (en) * 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6240616B1 (en) * 1997-04-15 2001-06-05 Advanced Cardiovascular Systems, Inc. Method of manufacturing a medicated porous metal prosthesis
US10028851B2 (en) * 1997-04-15 2018-07-24 Advanced Cardiovascular Systems, Inc. Coatings for controlling erosion of a substrate of an implantable medical device
US8172897B2 (en) * 1997-04-15 2012-05-08 Advanced Cardiovascular Systems, Inc. Polymer and metal composite implantable medical devices
US6776792B1 (en) 1997-04-24 2004-08-17 Advanced Cardiovascular Systems Inc. Coated endovascular stent
US20060025328A1 (en) * 1997-05-28 2006-02-02 Burns Patrick J Compositions suitable for controlled release of the hormone GnRH and its analogs
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
ES2284211T3 (es) 1997-06-05 2007-11-01 Bertex Pharma Gmbh Sistema multifasico.
AUPO907697A0 (en) 1997-09-09 1997-10-02 Day, Robert Edward Chemical supplementation of bone
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US6733767B2 (en) 1998-03-19 2004-05-11 Merck & Co., Inc. Liquid polymeric compositions for controlled release of bioactive substances
US7128927B1 (en) * 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
IL139813A0 (en) 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
CN1243543C (zh) * 1998-07-20 2006-03-01 派普泰克有限公司 生物植入物配方
ES2187201T3 (es) * 1998-10-14 2003-05-16 Cognis Deutschland Gmbh Empleo de esteroles y de esterolesteres a nanoescala.
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
EP2006300A3 (de) 1998-12-30 2009-03-11 Beth Israel Deaconess Medical Center, Inc. Charakterisierung einer Calciumkanalfamilie
WO2000040089A1 (en) * 1999-01-05 2000-07-13 Massachusetts Eye And Ear Infirmary Targeted transscleral controlled release drug delivery to the retina and choroid
US6955661B1 (en) 1999-01-25 2005-10-18 Atrium Medical Corporation Expandable fluoropolymer device for delivery of therapeutic agents and method of making
US6184011B1 (en) * 1999-03-22 2001-02-06 Cbd Technologies, Ltd Method of releasing solid matrix affinity adsorbed particulates
PT1163019E (pt) 1999-03-25 2007-12-06 Metabolix Inc Dispositivos médicos e aplicações de polímeros de poli-hidroxialcanoato
US6306425B1 (en) * 1999-04-09 2001-10-23 Southern Research Institute Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
GB9910505D0 (en) 1999-05-06 1999-07-07 Electrosols Ltd A method and apparatus for manufacturing consumable tablets
US6554851B1 (en) 1999-05-07 2003-04-29 Scimed Life Systems, Inc. Methods of sealing an injection site
DE60044904D1 (de) 1999-09-03 2010-10-14 Brigham & Womens Hospital Verfahren und zusammensetzungen zur behandlung von entzündungskrankheiten unter verwendung von cadherin-11-modulierenden agenzien
AU7604400A (en) * 1999-09-21 2001-04-24 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
TW524696B (en) * 1999-11-10 2003-03-21 Sumitomo Pharma Sustained-release drug formulations
DE50112157D1 (de) 2000-01-11 2007-04-19 Roland Bodmeier Kit zur implantation enthaltend eine trägerphase und ein lösungsmittel
US6575888B2 (en) * 2000-01-25 2003-06-10 Biosurface Engineering Technologies, Inc. Bioabsorbable brachytherapy device
CA2396640A1 (en) * 2000-01-28 2001-08-02 Smithkline Beecham Corporation Electrospun pharmaceutical compositions
US7097855B1 (en) 2000-01-31 2006-08-29 Massachusetts Institute Of Technology Transdermal thermal polymerization
US7074803B2 (en) * 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
US20030211974A1 (en) * 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
US7048541B2 (en) * 2000-04-04 2006-05-23 Nobel Biocare Ab Implant having attachment and hole-insert parts, and method for producing such an implant
SE516282C2 (sv) * 2000-04-04 2001-12-10 Nobel Biocare Ab Implantat försett med anslutnings- och hålisättningsdelar samt förfarande vid dylikt implantat
CA2404858A1 (en) * 2000-04-12 2001-10-25 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
JP4361710B2 (ja) 2000-04-19 2009-11-11 ジェネンテック・インコーポレーテッド 徐放製剤
WO2001097843A2 (en) 2000-06-22 2001-12-27 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
US6767899B1 (en) * 2000-08-29 2004-07-27 Leiner Health Services Corp. Composition and method for treatment of conditions having an inflammatory component
GB0024884D0 (en) * 2000-10-11 2000-11-22 Astrazeneca Ab Method
JP2002128697A (ja) * 2000-10-20 2002-05-09 Nonomura Tomosuke 口腔治療予防剤
US6783793B1 (en) 2000-10-26 2004-08-31 Advanced Cardiovascular Systems, Inc. Selective coating of medical devices
ATE481640T1 (de) 2000-11-27 2010-10-15 Minerva Biotechnologies Corp Diagnostika, drogenscreening und behandlung für krebs
AU2001297693A1 (en) * 2000-12-08 2002-09-12 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
US6623761B2 (en) 2000-12-22 2003-09-23 Hassan Emadeldin M. Method of making nanoparticles of substantially water insoluble materials
ATE427760T1 (de) * 2001-02-23 2009-04-15 Genentech Inc Erodierbare polymere zur injektion
CA2440770C (en) * 2001-03-22 2010-07-13 Battelle Memorial Institute Manufacturing dissolvable dosage forms
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US8137699B2 (en) * 2002-03-29 2012-03-20 Trustees Of Princeton University Process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use
US6695824B2 (en) 2001-04-16 2004-02-24 The United States Of America As Represented By The Secretary Of The Army Wound dressing system
WO2002089767A1 (en) 2001-05-03 2002-11-14 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
US20030022909A1 (en) 2001-06-05 2003-01-30 University Of Chicago Use of methylnaltrexone to treat immune suppression
US7455657B2 (en) * 2001-06-19 2008-11-25 Boston Scientific Scimed, Inc Method and apparatus to modify a fluid using a selectively permeable membrane
DK1397155T3 (en) * 2001-06-21 2015-12-07 Genentech Inc Prolonged release formulation
WO2003000156A1 (en) 2001-06-22 2003-01-03 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
US6565659B1 (en) 2001-06-28 2003-05-20 Advanced Cardiovascular Systems, Inc. Stent mounting assembly and a method of using the same to coat a stent
CN1604795B (zh) * 2001-08-17 2010-05-26 科勒制药股份公司 具有提高的活性的组合基序免疫刺激寡肽
US6488952B1 (en) 2001-08-28 2002-12-03 John P. Kennedy Semisolid therapeutic delivery system and combination semisolid, multiparticulate, therapeutic delivery system
CA2460334A1 (en) 2001-09-14 2003-03-27 Francis J. Martin Microfabricated nanopore device for sustained release of therapeutic agent
US7285304B1 (en) 2003-06-25 2007-10-23 Advanced Cardiovascular Systems, Inc. Fluid treatment of a polymeric coating on an implantable medical device
US7989018B2 (en) * 2001-09-17 2011-08-02 Advanced Cardiovascular Systems, Inc. Fluid treatment of a polymeric coating on an implantable medical device
US6863683B2 (en) * 2001-09-19 2005-03-08 Abbott Laboratoris Vascular Entities Limited Cold-molding process for loading a stent onto a stent delivery system
DK1455593T3 (da) 2001-10-06 2013-08-26 Merial Ltd Fremgangsmåder og sammensætninger til fremme af vækst og medfødt immunitet hos unge dyr
NZ531460A (en) * 2001-10-19 2005-05-27 Idexx Lab Inc Controlled release - over at least 4-15 days - of injectable compositions comprising a lipophilic counterion such a saturated or unsaturated C10-C18 fatty acid
US20030125292A1 (en) * 2001-11-07 2003-07-03 Sean Semple Mucoscal vaccine and methods for using the same
SE0103765D0 (sv) * 2001-11-09 2001-11-09 Astrazeneca Ab New use
MXPA04004665A (es) 2001-11-14 2004-09-10 Alza Corp Composiciones de deposito inyectable y uso de los mismos.
DE10161078A1 (de) * 2001-12-12 2003-08-28 Achim Goepferich Matrizes zur Stabilisierung und kontrollierten Freisetzung von Problemarzneistoffen
US8133501B2 (en) 2002-02-08 2012-03-13 Boston Scientific Scimed, Inc. Implantable or insertable medical devices for controlled drug delivery
US8685427B2 (en) * 2002-07-31 2014-04-01 Boston Scientific Scimed, Inc. Controlled drug delivery
US7479535B2 (en) * 2002-02-25 2009-01-20 Guilford Pharmaceuticals, Inc. Phosphorous-containing compounds with polymeric chains, and methods of making and using the same
EP1344538A1 (de) * 2002-03-14 2003-09-17 Degradable Solutions AG Poröses und bioabbaubares Implantatmaterial und Verfahren zu seiner Herstellung
JP2005526079A (ja) * 2002-03-15 2005-09-02 サイプレス バイオサイエンス， インコーポレイテッド 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤
US7074426B2 (en) * 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
AU2003230806B2 (en) 2002-04-04 2009-05-07 Zoetis Belgium S.A. Immunostimulatory G,U-containing oligoribonucleotides
US20040096498A1 (en) * 2002-04-29 2004-05-20 Alvin Kershman Oral pharmaceutical delivery system with improved sustained release
WO2003092665A2 (en) * 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
US7670769B2 (en) 2002-05-09 2010-03-02 The Brigham And Women's Hospital, Inc. IL1RL-1 as a cardiovascular disease marker and therapeutic target
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
US20030224023A1 (en) * 2002-05-29 2003-12-04 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Cosmetic compositions with hydroxy amine salts of malonic acid
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
EP1539193A4 (de) * 2002-07-03 2010-05-05 Pericor Science Inc Zusammensetzungen von hyaluronsäure und verwendungsverfahren
ES2295647T3 (es) * 2002-07-15 2008-04-16 Alcon, Inc. Composiciones de implante farmaceuticas lipofilas, no polimeras, para uso intraocular.
US20070184089A1 (en) * 2002-07-15 2007-08-09 Alcon, Inc. Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
US8084054B2 (en) * 2002-07-15 2011-12-27 Novartis Ag Bioerodible film for ophthalmic drug delivery
US7727549B2 (en) * 2002-07-15 2010-06-01 Alcon, Inc. Pharmaceutical compositions for otic use
CA2494342A1 (en) 2002-07-31 2004-02-12 Alza Corporation Injectable depot compositions and uses thereof
US8501215B2 (en) 2002-07-31 2013-08-06 Guohua Chen Injectable multimodal polymer depot compositions and uses thereof
US8920826B2 (en) 2002-07-31 2014-12-30 Boston Scientific Scimed, Inc. Medical imaging reference devices
TW200410714A (en) * 2002-08-07 2004-07-01 Smithkline Beecham Corp Electrospun amorphous pharmaceutical compositions
US8193318B2 (en) * 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) * 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) * 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en) * 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US7425620B2 (en) * 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
US8044180B2 (en) * 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
DE10238310A1 (de) * 2002-08-21 2004-03-04 Erich Jaeger Gmbh Elektrodenanordnung
US20030049698A1 (en) * 2002-10-08 2003-03-13 Wang Timothy C. Diagnosis and treatment of gastrointestinal disease
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
CN1753687A (zh) 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
US20060271168A1 (en) * 2002-10-30 2006-11-30 Klaus Kleine Degradable medical device
WO2004043434A1 (en) * 2002-11-14 2004-05-27 Shear/Kershman Laboratories, Inc. Oral testosterone delivery system with improved sustained release
US20080305177A1 (en) * 2002-11-14 2008-12-11 Alvin Kershman Method of administering testosterone
EP2363410B1 (de) 2002-11-27 2017-10-11 Minerva Biotechnologies Corporation MUC1-Isoformen
SI1575569T1 (sl) 2002-12-13 2010-12-31 Durect Corp Oralni sistem dostave zdravila, ki obsega visokoviskozne tekoče nosilne materiale
US8435550B2 (en) 2002-12-16 2013-05-07 Abbot Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7758881B2 (en) 2004-06-30 2010-07-20 Advanced Cardiovascular Systems, Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP2368578A1 (de) 2003-01-09 2011-09-28 Macrogenics, Inc. Identifizierung und Herstellung von Antikörpern mit abweichenden FC-Regionen und Anwendungsverfahren dafür
EP2052713A3 (de) 2003-01-13 2009-05-20 Macrogenics, Inc. Lösliche FcgammaR-Fusionsproteine und Verfahren zu deren Verwendung
US20040228830A1 (en) * 2003-01-28 2004-11-18 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
SI2325302T1 (sl) 2003-02-11 2016-05-31 Shire Human Genetic Therapies, Inc. Celice, ki soizražajo sulfatazo in c-formilglicin generirajoči encim ter postopki in uporabe le-teh
US20060167435A1 (en) * 2003-02-18 2006-07-27 Adamis Anthony P Transscleral drug delivery device and related methods
US20060154910A1 (en) * 2003-02-20 2006-07-13 Bingaman David P Use of steroids to treat ocular disorders
AU2004212900A1 (en) * 2003-02-20 2004-09-02 Alcon, Inc. Formulations of glucocorticoids to treat pathologic ocular angiogenesis
US8524899B2 (en) * 2003-03-04 2013-09-03 California Institute Of Technology Alternative heterocycles for DNA recognition
DE10312346A1 (de) * 2003-03-20 2004-09-30 Bayer Healthcare Ag Kontrolliertes Freisetzungssystem
EP1608403A2 (de) * 2003-04-02 2005-12-28 Coley Pharmaceutical Group, Ltd. Immunostimulatorische nukleinsäure öl-in-wasser emulsionen zur topischen anwendung
CA2534816A1 (en) 2003-06-12 2004-12-23 Evan Newell Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
CA2527121A1 (en) * 2003-06-13 2004-12-29 Alcon, Inc. Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
US20070110804A1 (en) * 2003-06-20 2007-05-17 Royer Biomedical, Inc. Drug polymer complexes
JP5229768B2 (ja) * 2003-06-26 2013-07-03 シヴィダ・ユーエス・インコーポレイテッド Ｉｎ−Ｓｉｔｕゲル化薬物輸送システム
ES2379466T3 (es) 2003-06-26 2012-04-26 Psivida Us, Inc. Sistema de suministro de fármacos de liberación sostenida bioerosionables
US20060173171A1 (en) * 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
US8021331B2 (en) * 2003-09-15 2011-09-20 Atrium Medical Corporation Method of coating a folded medical device
US7198675B2 (en) 2003-09-30 2007-04-03 Advanced Cardiovascular Systems Stent mandrel fixture and method for selectively coating surfaces of a stent
WO2005034979A2 (en) * 2003-10-11 2005-04-21 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
AU2004287439A1 (en) * 2003-10-29 2005-05-19 Idexx Laboratories, Inc. Salts of pharmacologically active compounds
EP2248895B8 (de) 2003-12-19 2016-09-21 Autotelic LLC Kombinations-therapie die ein TGF-beta Antagonisten mit einem Chemotherapeutikum assoziiert
US7563324B1 (en) 2003-12-29 2009-07-21 Advanced Cardiovascular Systems Inc. System and method for coating an implantable medical device
US20050154343A1 (en) * 2004-01-14 2005-07-14 Mohinder Singh Soft tip applicator for relieving mouth pain
US7452730B2 (en) * 2004-01-16 2008-11-18 California Institute Of Technology DNA-binding polymers
US8048086B2 (en) 2004-02-25 2011-11-01 Femasys Inc. Methods and devices for conduit occlusion
US8052669B2 (en) 2004-02-25 2011-11-08 Femasys Inc. Methods and devices for delivery of compositions to conduits
US9238127B2 (en) 2004-02-25 2016-01-19 Femasys Inc. Methods and devices for delivering to conduit
US8048101B2 (en) 2004-02-25 2011-11-01 Femasys Inc. Methods and devices for conduit occlusion
EP1568383A3 (de) 2004-02-27 2005-11-16 Antisense Pharma GmbH Verwendung eines Oligonukleotide oder seiner aktiven Ableitung für die Zubereitung einer pharmazeutische Zusammensetzung zur Hemmung der Metastasenbildung in Krebsbehandlung
AU2005218759B2 (en) * 2004-02-27 2009-07-16 Antisense Pharma Gmbh Pharmaceutical composition
MXPA06011796A (es) * 2004-04-16 2007-05-07 Macrogenics Inc Anticuerpos especificos de fc(riib y metodos para el uso de los mismos.
EP2468769A1 (de) 2004-04-21 2012-06-27 The Brigham and Women's Hospital, Inc. Poly-N-acetylglucosamin (PNAG/DPNAG)-bindenden Peptide und Verwendungsverfahren dafür
US7553377B1 (en) 2004-04-27 2009-06-30 Advanced Cardiovascular Systems, Inc. Apparatus and method for electrostatic coating of an abluminal stent surface
US8163030B2 (en) * 2004-05-06 2012-04-24 Degradable Solutions Ag Biocompatible bone implant compositions and methods for repairing a bone defect
MXPA06012601A (es) 2004-05-10 2007-05-10 Macrogenics Inc Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
EP1604693A1 (de) 2004-06-09 2005-12-14 Scil Technology GmbH In-situ hergestelltes Gerüst, dessen Herstellungsverfahren und dessen Verwendung
US7854943B2 (en) * 2004-06-24 2010-12-21 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US7858115B2 (en) * 2004-06-24 2010-12-28 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US7618651B2 (en) * 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
US8568469B1 (en) 2004-06-28 2013-10-29 Advanced Cardiovascular Systems, Inc. Stent locking element and a method of securing a stent on a delivery system
US8241554B1 (en) 2004-06-29 2012-08-14 Advanced Cardiovascular Systems, Inc. Method of forming a stent pattern on a tube
US8747879B2 (en) * 2006-04-28 2014-06-10 Advanced Cardiovascular Systems, Inc. Method of fabricating an implantable medical device to reduce chance of late inflammatory response
US7731890B2 (en) * 2006-06-15 2010-06-08 Advanced Cardiovascular Systems, Inc. Methods of fabricating stents with enhanced fracture toughness
US7971333B2 (en) * 2006-05-30 2011-07-05 Advanced Cardiovascular Systems, Inc. Manufacturing process for polymetric stents
US8747878B2 (en) 2006-04-28 2014-06-10 Advanced Cardiovascular Systems, Inc. Method of fabricating an implantable medical device by controlling crystalline structure
US8778256B1 (en) 2004-09-30 2014-07-15 Advanced Cardiovascular Systems, Inc. Deformation of a polymer tube in the fabrication of a medical article
US20060020330A1 (en) * 2004-07-26 2006-01-26 Bin Huang Method of fabricating an implantable medical device with biaxially oriented polymers
US20060041102A1 (en) * 2004-08-23 2006-02-23 Advanced Cardiovascular Systems, Inc. Implantable devices comprising biologically absorbable polymers having constant rate of degradation and methods for fabricating the same
US9283099B2 (en) * 2004-08-25 2016-03-15 Advanced Cardiovascular Systems, Inc. Stent-catheter assembly with a releasable connection for stent retention
JP2008511678A (ja) * 2004-09-02 2008-04-17 イェール ユニバーシティ マイクロｒｎａによるオンコジーンの調節
US7229471B2 (en) * 2004-09-10 2007-06-12 Advanced Cardiovascular Systems, Inc. Compositions containing fast-leaching plasticizers for improved performance of medical devices
AU2005336092B2 (en) * 2004-09-14 2010-05-27 Cynthia C. Bamdad Methods for diagnosis and treatment of cancer
EP3103477A1 (de) 2004-09-17 2016-12-14 Durect Corporation Anhaltende lokalanästhetikumzusammensetzung mit saib
WO2006037106A2 (en) 2004-09-24 2006-04-06 Rfe Pharma Llc Carboxy-amido-triazoles for the localized treatment of ocular diseases
US20160106717A1 (en) 2004-09-24 2016-04-21 Gen Pharma Holdings LLC Cai-based systems and methods for the localized treatment of uveitis
US20060074422A1 (en) * 2004-09-27 2006-04-06 Story Brooks J Suture anchor and void filler combination
US9000040B2 (en) * 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9801982B2 (en) * 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US8312836B2 (en) * 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
WO2006036982A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Drug delivery coating for use with a stent
US8367099B2 (en) * 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
EP1811933B1 (de) * 2004-09-28 2016-03-23 Atrium Medical Corporation Barriereschicht
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20090011116A1 (en) * 2004-09-28 2009-01-08 Atrium Medical Corporation Reducing template with coating receptacle containing a medical device to be coated
US8173062B1 (en) 2004-09-30 2012-05-08 Advanced Cardiovascular Systems, Inc. Controlled deformation of a polymer tube in fabricating a medical article
US7875233B2 (en) 2004-09-30 2011-01-25 Advanced Cardiovascular Systems, Inc. Method of fabricating a biaxially oriented implantable medical device
US8043553B1 (en) 2004-09-30 2011-10-25 Advanced Cardiovascular Systems, Inc. Controlled deformation of a polymer tube with a restraining surface in fabricating a medical article
CN101890167B (zh) * 2004-10-01 2017-03-01 拉姆斯科股份有限公司 可方便植入的缓释药物组合物
EP1804751A2 (de) * 2004-10-04 2007-07-11 QLT USA, Inc. Okulare abgabe von polymer-abgabeformulierungen
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
US20070059350A1 (en) * 2004-12-13 2007-03-15 Kennedy John P Agents for controlling biological fluids and methods of use thereof
US20060127437A1 (en) * 2004-12-13 2006-06-15 Misty Anderson Kennedy Semisolid system and combination semisolid, multiparticulate system for sealing tissues and/or controlling biological fluids
US8535709B2 (en) * 2004-12-13 2013-09-17 Southeastern Medical Technologies, Llc Agents for controlling biological fluids and methods of use thereof
US7632307B2 (en) 2004-12-16 2009-12-15 Advanced Cardiovascular Systems, Inc. Abluminal, multilayer coating constructs for drug-delivery stents
PL1838716T3 (pl) * 2005-01-05 2011-09-30 Lilly Co Eli Dihydrat embonianu olanzapiny
DE102005002703C5 (de) 2005-01-19 2013-07-04 Heraeus Kulzer Gmbh Antibiotische Beschichtung von Implantaten sowie Verfahren zur antibiotischen Beschichtung
WO2006112941A2 (en) * 2005-02-16 2006-10-26 Cytori Therapeutics, Inc. Resorbable hollow devices for implantation and delivery of therapeutic agents
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2006096626A2 (en) * 2005-03-07 2006-09-14 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
ES2720288T3 (es) 2005-03-30 2019-07-19 Minerva Biotechnologies Corp Proliferación de células que expresan MUC1
CA2610292C (en) 2005-03-30 2015-06-02 Minerva Biotechnologies Corporation Proliferation of muc1 expressing cells
US20060224226A1 (en) * 2005-03-31 2006-10-05 Bin Huang In-vivo radial orientation of a polymeric implantable medical device
US7381048B2 (en) * 2005-04-12 2008-06-03 Advanced Cardiovascular Systems, Inc. Stents with profiles for gripping a balloon catheter and molds for fabricating stents
US8864730B2 (en) 2005-04-12 2014-10-21 Rochester Medical Corporation Silicone rubber male external catheter with absorbent and adhesive
EP3479844B1 (de) 2005-04-15 2023-11-22 MacroGenics, Inc. Kovalente diabodies und verwendungen davon
AU2006236294A1 (en) 2005-04-19 2006-10-26 Eli Lilly And Company Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
US20060241076A1 (en) * 2005-04-26 2006-10-26 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
EP1879632A2 (de) * 2005-04-29 2008-01-23 Atrium Medical Corporation Arzneistoffzuführungsbeschichtung zur verwendung bei einer medizinischen vorrichtung sowie verfahren zur behandlung von gefässverletzung
NZ562954A (en) 2005-05-05 2009-10-30 Antisense Pharma Gmbh Use of low doses of oligonucleotides antisense to TGF-beta, VEGF, interleukin-10, C-JUN, C-FOS or prostaglandin E2 genes in the treatment of tumors
US20060257448A1 (en) * 2005-05-10 2006-11-16 The University Of Zurich Resorbable polymer composition, implant and method of making implant
US7291166B2 (en) * 2005-05-18 2007-11-06 Advanced Cardiovascular Systems, Inc. Polymeric stent patterns
US20060282028A1 (en) * 2005-06-10 2006-12-14 Howard Pamela A Wound Management System
US7622070B2 (en) 2005-06-20 2009-11-24 Advanced Cardiovascular Systems, Inc. Method of manufacturing an implantable polymeric medical device
EP2163562B1 (de) 2005-06-21 2013-09-18 XOMA Technology Ltd. IL-1 beta bindende Antikörper und deren Fragmente
US8354384B2 (en) * 2005-06-23 2013-01-15 Yale University Anti-aging micrornas
US7727235B2 (en) * 2005-06-29 2010-06-01 Ethicon, Inc. Medical fixation devices with improved torsional drive head
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US7658880B2 (en) * 2005-07-29 2010-02-09 Advanced Cardiovascular Systems, Inc. Polymeric stent polishing method and apparatus
US7297758B2 (en) * 2005-08-02 2007-11-20 Advanced Cardiovascular Systems, Inc. Method for extending shelf-life of constructs of semi-crystallizable polymers
CA2618681C (en) 2005-08-10 2015-10-27 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US20070038290A1 (en) * 2005-08-15 2007-02-15 Bin Huang Fiber reinforced composite stents
US7476245B2 (en) * 2005-08-16 2009-01-13 Advanced Cardiovascular Systems, Inc. Polymeric stent patterns
US8362086B2 (en) 2005-08-19 2013-01-29 Merial Limited Long acting injectable formulations
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
US20070045252A1 (en) * 2005-08-23 2007-03-01 Klaus Kleine Laser induced plasma machining with a process gas
US20070045255A1 (en) * 2005-08-23 2007-03-01 Klaus Kleine Laser induced plasma machining with an optimized process gas
US9248034B2 (en) * 2005-08-23 2016-02-02 Advanced Cardiovascular Systems, Inc. Controlled disintegrating implantable medical devices
US8507439B2 (en) 2005-08-29 2013-08-13 Angela Shashoua Neuroprotective and neurorestorative method and compositions
DK1937252T3 (da) * 2005-09-19 2017-11-20 Neuronascent Inc Sammensætninger til stimulering af neurogenese og hæmning af neuronal degeneration
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US20070134244A1 (en) * 2005-10-14 2007-06-14 Alcon, Inc. Combination treatment for pathologic ocular angiogenesis
WO2007047781A2 (en) * 2005-10-15 2007-04-26 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
CA2632697C (en) * 2005-11-09 2016-01-05 Protemix Corporation Limited Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits
US8658608B2 (en) * 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
US7662949B2 (en) 2005-11-25 2010-02-16 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
US7867547B2 (en) 2005-12-19 2011-01-11 Advanced Cardiovascular Systems, Inc. Selectively coating luminal surfaces of stents
JP5276448B2 (ja) * 2005-12-22 2013-08-28 オークウッド ラボラトリーズ，エル．エル．シー． 昇華可能な持続放出デリバリーシステム及びその製造方法
US20070151961A1 (en) * 2006-01-03 2007-07-05 Klaus Kleine Fabrication of an implantable medical device with a modified laser beam
US20070156230A1 (en) 2006-01-04 2007-07-05 Dugan Stephen R Stents with radiopaque markers
US7951185B1 (en) 2006-01-06 2011-05-31 Advanced Cardiovascular Systems, Inc. Delivery of a stent at an elevated temperature
MX2008009125A (es) 2006-01-18 2008-10-23 Qps Llc Composiciones farmaceuticas con estabilidad mejorada.
US20070179219A1 (en) * 2006-01-31 2007-08-02 Bin Huang Method of fabricating an implantable medical device using gel extrusion and charge induced orientation
JP2009529331A (ja) * 2006-03-10 2009-08-20 マクロジェニクス，インコーポレーテッド 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
US20070219268A1 (en) * 2006-03-16 2007-09-20 Bionumerik Pharmaceuticals, Inc. Anti-cancer activity augmentation compounds and formulations and methods of use thereof
US7964210B2 (en) * 2006-03-31 2011-06-21 Abbott Cardiovascular Systems Inc. Degradable polymeric implantable medical devices with a continuous phase and discrete phase
US20090325944A1 (en) * 2006-04-12 2009-12-31 Suzanne Walker Kahne Methods and Compositions for Modulating Glycosylation
US20070254012A1 (en) * 2006-04-28 2007-11-01 Ludwig Florian N Controlled degradation and drug release in stents
US8003156B2 (en) 2006-05-04 2011-08-23 Advanced Cardiovascular Systems, Inc. Rotatable support elements for stents
US7761968B2 (en) * 2006-05-25 2010-07-27 Advanced Cardiovascular Systems, Inc. Method of crimping a polymeric stent
US7951194B2 (en) 2006-05-26 2011-05-31 Abbott Cardiovascular Sysetms Inc. Bioabsorbable stent with radiopaque coating
US7786270B2 (en) * 2006-05-26 2010-08-31 Macrogenics, Inc. Humanized FcγRIIB-specific antibodies and methods of use thereof
US20130325104A1 (en) 2006-05-26 2013-12-05 Abbott Cardiovascular Systems Inc. Stents With Radiopaque Markers
US20070282434A1 (en) * 2006-05-30 2007-12-06 Yunbing Wang Copolymer-bioceramic composite implantable medical devices
US8343530B2 (en) * 2006-05-30 2013-01-01 Abbott Cardiovascular Systems Inc. Polymer-and polymer blend-bioceramic composite implantable medical devices
US7959940B2 (en) * 2006-05-30 2011-06-14 Advanced Cardiovascular Systems, Inc. Polymer-bioceramic composite implantable medical devices
US7842737B2 (en) 2006-09-29 2010-11-30 Abbott Cardiovascular Systems Inc. Polymer blend-bioceramic composite implantable medical devices
US20080058916A1 (en) * 2006-05-31 2008-03-06 Bin Huang Method of fabricating polymeric self-expandable stent
US8486135B2 (en) 2006-06-01 2013-07-16 Abbott Cardiovascular Systems Inc. Implantable medical devices fabricated from branched polymers
US8034287B2 (en) * 2006-06-01 2011-10-11 Abbott Cardiovascular Systems Inc. Radiation sterilization of medical devices
US20070281073A1 (en) * 2006-06-01 2007-12-06 Gale David C Enhanced adhesion of drug delivery coatings on stents
US20070282433A1 (en) * 2006-06-01 2007-12-06 Limon Timothy A Stent with retention protrusions formed during crimping
US20070286941A1 (en) * 2006-06-13 2007-12-13 Bin Huang Surface treatment of a polymeric stent
US8603530B2 (en) 2006-06-14 2013-12-10 Abbott Cardiovascular Systems Inc. Nanoshell therapy
US8048448B2 (en) 2006-06-15 2011-11-01 Abbott Cardiovascular Systems Inc. Nanoshells for drug delivery
US8535372B1 (en) 2006-06-16 2013-09-17 Abbott Cardiovascular Systems Inc. Bioabsorbable stent with prohealing layer
US20070290412A1 (en) * 2006-06-19 2007-12-20 John Capek Fabricating a stent with selected properties in the radial and axial directions
US8333000B2 (en) 2006-06-19 2012-12-18 Advanced Cardiovascular Systems, Inc. Methods for improving stent retention on a balloon catheter
EP2029169A2 (de) 2006-06-20 2009-03-04 Transgene S.A. Rekombinanter viraler impfstoff
US8017237B2 (en) 2006-06-23 2011-09-13 Abbott Cardiovascular Systems, Inc. Nanoshells on polymers
US9072820B2 (en) * 2006-06-26 2015-07-07 Advanced Cardiovascular Systems, Inc. Polymer composite stent with polymer particles
DE102006029247A1 (de) * 2006-06-26 2007-12-27 Biotronik Vi Patent Ag Implantat mit einer Cholesterol- oder Cholesterolester-haltigen Beschichtung
EP2032159B1 (de) * 2006-06-26 2015-01-07 MacroGenics, Inc. Kombination aus fcgammariib-antikörpern und cd20-spezifischen antikörpern sowie verwendungsverfahren dafür
PT2029173T (pt) 2006-06-26 2016-11-02 Macrogenics Inc Anticorpos específicos fc rib e seus métodos de uso
US8128688B2 (en) 2006-06-27 2012-03-06 Abbott Cardiovascular Systems Inc. Carbon coating on an implantable device
US20070299511A1 (en) * 2006-06-27 2007-12-27 Gale David C Thin stent coating
US7794776B1 (en) 2006-06-29 2010-09-14 Abbott Cardiovascular Systems Inc. Modification of polymer stents with radiation
US7740791B2 (en) * 2006-06-30 2010-06-22 Advanced Cardiovascular Systems, Inc. Method of fabricating a stent with features by blow molding
US20080009938A1 (en) * 2006-07-07 2008-01-10 Bin Huang Stent with a radiopaque marker and method for making the same
US7823263B2 (en) 2006-07-11 2010-11-02 Abbott Cardiovascular Systems Inc. Method of removing stent islands from a stent
MX2009000434A (es) 2006-07-11 2009-01-29 Qps Llc Composiciones farmaceuticas para la distribucion de liberacion sostenida de peptidos.
US20080014244A1 (en) * 2006-07-13 2008-01-17 Gale David C Implantable medical devices and coatings therefor comprising physically crosslinked block copolymers
US7757543B2 (en) * 2006-07-13 2010-07-20 Advanced Cardiovascular Systems, Inc. Radio frequency identification monitoring of stents
US7998404B2 (en) * 2006-07-13 2011-08-16 Advanced Cardiovascular Systems, Inc. Reduced temperature sterilization of stents
US7794495B2 (en) * 2006-07-17 2010-09-14 Advanced Cardiovascular Systems, Inc. Controlled degradation of stents
US7886419B2 (en) * 2006-07-18 2011-02-15 Advanced Cardiovascular Systems, Inc. Stent crimping apparatus and method
US20080091262A1 (en) * 2006-10-17 2008-04-17 Gale David C Drug delivery after biodegradation of the stent scaffolding
US8016879B2 (en) * 2006-08-01 2011-09-13 Abbott Cardiovascular Systems Inc. Drug delivery after biodegradation of the stent scaffolding
US9173733B1 (en) 2006-08-21 2015-11-03 Abbott Cardiovascular Systems Inc. Tracheobronchial implantable medical device and methods of use
US7923022B2 (en) * 2006-09-13 2011-04-12 Advanced Cardiovascular Systems, Inc. Degradable polymeric implantable medical devices with continuous phase and discrete phase
WO2008147426A2 (en) * 2006-10-04 2008-12-04 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20080112961A1 (en) * 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
PL2117521T3 (pl) 2006-11-03 2012-11-30 Durect Corp Transdermalne systemy dostarczania zawierające bupiwakainę
EP2083875B1 (de) * 2006-11-06 2013-03-27 Atrium Medical Corporation Beschichtetes chirurgisches netz
US9492596B2 (en) * 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
US7718649B1 (en) * 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
EP2066321A2 (de) * 2006-11-20 2009-06-10 Lutonix, Inc. Behandlung von asthma und chronisch obstruktiver lungenerkrankung mit antiproliferativen und entzündungshemmenden mitteln
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
US8099849B2 (en) 2006-12-13 2012-01-24 Abbott Cardiovascular Systems Inc. Optimizing fracture toughness of polymeric stent
US7695718B2 (en) 2006-12-20 2010-04-13 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
US8642093B2 (en) * 2007-10-30 2014-02-04 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US7862598B2 (en) * 2007-10-30 2011-01-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US7975699B2 (en) 2007-10-30 2011-07-12 The Invention Science Fund I, Llc Condoms configured to facilitate release of nitric oxide
US20110190604A1 (en) * 2006-12-22 2011-08-04 Hyde Roderick A Nitric oxide sensors and systems
US8221690B2 (en) * 2007-10-30 2012-07-17 The Invention Science Fund I, Llc Systems and devices that utilize photolyzable nitric oxide donors
WO2008086529A2 (en) * 2007-01-11 2008-07-17 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
WO2008097525A2 (en) 2007-02-05 2008-08-14 Potentia Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
US9187593B2 (en) 2007-02-15 2015-11-17 Tolmar Therapeutics, Inc. Low burst polymers and methods to produce polymer
US20100111943A1 (en) * 2007-03-22 2010-05-06 Medical College Of Georgia Research Institute, Inc Compositions and methods for inhibiting cancer metastasis
US20080243228A1 (en) * 2007-03-28 2008-10-02 Yunbing Wang Implantable medical devices fabricated from block copolymers
US8262723B2 (en) 2007-04-09 2012-09-11 Abbott Cardiovascular Systems Inc. Implantable medical devices fabricated from polymer blends with star-block copolymers
DK2644205T3 (en) 2007-04-12 2018-09-24 Brigham & Womens Hospital Inc Targeting ABCB5 for Cancer Therapy
WO2008130619A2 (en) * 2007-04-20 2008-10-30 Trustees Of Boston College A composition comprising an inhibitor of pde4 and/or pde7
US8747872B2 (en) * 2007-05-02 2014-06-10 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
WO2008142509A2 (en) * 2007-05-17 2008-11-27 Coley Pharmaceutical Group, Inc. Class a oligonucleotides with immunostimulatory potency
JP2010531807A (ja) 2007-05-25 2010-09-30 トルマー セラピューティクス， インコーポレイテッド リスペリドン化合物の徐放送達製剤
US7829008B2 (en) * 2007-05-30 2010-11-09 Abbott Cardiovascular Systems Inc. Fabricating a stent from a blow molded tube
US7959857B2 (en) * 2007-06-01 2011-06-14 Abbott Cardiovascular Systems Inc. Radiation sterilization of medical devices
US8202528B2 (en) * 2007-06-05 2012-06-19 Abbott Cardiovascular Systems Inc. Implantable medical devices with elastomeric block copolymer coatings
US20080306582A1 (en) * 2007-06-05 2008-12-11 Yunbing Wang Implantable medical devices with elastomeric copolymer coatings
US8293260B2 (en) * 2007-06-05 2012-10-23 Abbott Cardiovascular Systems Inc. Elastomeric copolymer coatings containing poly (tetramethyl carbonate) for implantable medical devices
US8425591B1 (en) 2007-06-11 2013-04-23 Abbott Cardiovascular Systems Inc. Methods of forming polymer-bioceramic composite medical devices with bioceramic particles
WO2008156676A1 (en) * 2007-06-15 2008-12-24 President And Fellows Of Harvard College Methods and compositions for detecting and modulating o-glycosylation
ES2702087T3 (es) 2007-06-21 2019-02-27 Macrogenics Inc Diacuerpos covalentes y sus usos
WO2009002456A2 (en) * 2007-06-21 2008-12-31 Massachusetts Institute Of Technology Methods and compositions relating to progenitor cells
KR101600054B1 (ko) 2007-06-21 2016-03-04 뉴로내슨트, 아이엔씨. 이소티아졸로피리미디논을 사용하는 신경 발생을 자극하고 신경 변성을 억제하는 방법 및 조성물
US8048441B2 (en) 2007-06-25 2011-11-01 Abbott Cardiovascular Systems, Inc. Nanobead releasing medical devices
US7901452B2 (en) * 2007-06-27 2011-03-08 Abbott Cardiovascular Systems Inc. Method to fabricate a stent having selected morphology to reduce restenosis
US7955381B1 (en) 2007-06-29 2011-06-07 Advanced Cardiovascular Systems, Inc. Polymer-bioceramic composite implantable medical device with different types of bioceramic particles
WO2009022215A1 (en) 2007-08-13 2009-02-19 Pfizer Inc. Combination motif immune stimulatory oligonucleotides with improved activity
US8877508B2 (en) * 2007-10-30 2014-11-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US8980332B2 (en) 2007-10-30 2015-03-17 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US10080823B2 (en) 2007-10-30 2018-09-25 Gearbox Llc Substrates for nitric oxide releasing devices
US8349262B2 (en) * 2007-10-30 2013-01-08 The Invention Science Fund I, Llc Nitric oxide permeable housings
US20090112055A1 (en) * 2007-10-30 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Sleeves configured to facilitate release of nitric oxide
US7897399B2 (en) 2007-10-30 2011-03-01 The Invention Science Fund I, Llc Nitric oxide sensors and systems
JP2011502990A (ja) * 2007-11-05 2011-01-27 ボーシュ アンド ローム インコーポレイティド 薬物送達用ビヒクルとしての水非混和性物質
EP3326621A1 (de) * 2007-12-06 2018-05-30 Durect Corporation Orale arzneimitteldosierformen
HRP20141194T1 (hr) 2007-12-20 2015-04-24 Xoma (Us) Llc Postupci lijeäśenja gihta
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
EP2257626A2 (de) * 2008-03-01 2010-12-08 Abraxis BioScience, LLC Behandlung, diagnostikum und verfahren zur entdeckung eines antagonisten unter verwendung sparc-spezifischer mirnas
CN102014891B (zh) 2008-03-14 2013-12-18 比奥纽默里克药物公司 增加癌症患者存活时间的化合物的组合物和使用方法
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
US8669349B2 (en) 2008-04-02 2014-03-11 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
PL2247304T3 (pl) * 2008-04-02 2017-01-31 Macrogenics, Inc. Przeciwciała specyficzne wobec HER2/neu oraz sposoby ich zastosowania
CN102144163A (zh) 2008-04-10 2011-08-03 麻省理工学院 关于鉴定和使用靶向癌症干细胞的试剂的方法
US20100227853A1 (en) * 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
US20110076296A1 (en) 2008-04-25 2011-03-31 Innate Pharma S.A. TLR3 Agonist Compositions
CA2723716A1 (en) * 2008-05-07 2009-11-12 Abraxis Bioscience, Llc Enhancement of drug therapy by mirna
US9486531B2 (en) * 2008-06-03 2016-11-08 Indivior Uk Limited Dehydrated hydrogel inclusion complex of a bioactive agent with flowable drug delivery system
AU2009255675B2 (en) * 2008-06-03 2014-10-09 Tolmar Therapeutics, Inc. Controlled release copolymer formulation with improved release kinetics
WO2010033279A2 (en) * 2008-06-04 2010-03-25 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
US8598342B2 (en) 2008-06-12 2013-12-03 President And Fellows Of Harvard College Methods and compounds for antimicrobial intervention
EP2326304A2 (de) 2008-07-17 2011-06-01 Merial Limited Verfahren zur verbesserung der stabilität von polyorthoestern und ihren formulierungen
EP2323679A4 (de) 2008-07-25 2012-08-22 Univ Colorado Clip-hemmer und verfahren zur modulierung der immunfunktion
US8614189B2 (en) * 2008-09-24 2013-12-24 University Of Connecticut Carbon nanotube composite scaffolds for bone tissue engineering
JP5722782B2 (ja) * 2008-09-26 2015-05-27 ナノバイオ コーポレーション ナノエマルジョン治療用組成物及びその使用方法
US12171463B2 (en) 2008-10-03 2024-12-24 Femasys Inc. Contrast agent generation and injection system for sonographic imaging
US9554826B2 (en) 2008-10-03 2017-01-31 Femasys, Inc. Contrast agent injection system for sonographic imaging
US10070888B2 (en) * 2008-10-03 2018-09-11 Femasys, Inc. Methods and devices for sonographic imaging
KR20160017117A (ko) 2008-10-09 2016-02-15 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
ES2796111T3 (es) 2008-11-14 2020-11-25 Brigham & Womens Hospital Inc Métodos terapéuticos relacionados con células madre cancerosas
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
SG172254A1 (en) 2008-12-19 2011-07-28 Macrogenics Inc Covalent diabodies and uses thereof
EP2403539A2 (de) 2009-03-02 2012-01-11 Massachusetts Institute of Technology Verfahren und systeme zur behandlung und/oder diagnose
US8309356B2 (en) * 2009-04-01 2012-11-13 Yale University Pseudocomplementary oligonucleotides for targeted gene therapy
ES2550181T3 (es) 2009-05-14 2015-11-05 Bayer Intellectual Property Gmbh Respuesta inmunitaria reforzada en especies aviares
JP2012528858A (ja) 2009-06-01 2012-11-15 プレジデント アンド フェロウズ オブ ハーバード カレッジ Ｏ−ＧｌｃＮＡｃ転移酵素阻害剤およびその使用
US20100310623A1 (en) * 2009-06-05 2010-12-09 Laurencin Cato T Synergetic functionalized spiral-in-tubular bone scaffolds
BRPI1014031A2 (pt) 2009-06-16 2018-02-20 Univ Michigan Regents vacinas de nanoemulsão
US20110146680A1 (en) * 2009-06-25 2011-06-23 Conway Anthony J Silicone catheter containing chlorhexidine gluconate
US9089573B2 (en) 2009-07-22 2015-07-28 University Of Massachusetts Methods and compositions to reduce oxidative stress
PE20121495A1 (es) 2009-07-30 2012-11-19 Antisense Pharma Gmbh Combinacion de un agente quimioterapeutico y un inhibidor del sistema tgf-beta
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
EP2287304A1 (de) 2009-08-17 2011-02-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Neuartige Behandlung von Patienten nach Stentimplantation oder Ballondilatation und neuartige Arzneimittel eluierende Stents
RU2580320C2 (ru) 2009-08-18 2016-04-10 Вентиркс Фармасьютикалз, Инк. Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора
JP5756804B2 (ja) 2009-08-18 2015-07-29 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッドＶｅｎｔｉＲｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｔｏｌｌ様レセプターモジュレーターとしての置換ベンゾアゼピン
CN102666874B (zh) 2009-10-07 2016-06-01 宏观基因有限公司 由于岩藻糖基化程度的改变而表现出改善的效应子功能的含Fc区的多肽及其使用方法
US8568471B2 (en) 2010-01-30 2013-10-29 Abbott Cardiovascular Systems Inc. Crush recoverable polymer scaffolds
US8808353B2 (en) 2010-01-30 2014-08-19 Abbott Cardiovascular Systems Inc. Crush recoverable polymer scaffolds having a low crossing profile
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
DE102010014113A1 (de) * 2010-04-07 2011-10-13 Acino Ag Freisetzungsverfahren für Implantate
WO2011133803A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for targeted inactivation of hiv cell surface receptors
WO2011133802A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
KR20130107203A (ko) 2010-05-04 2013-10-01 더 브리검 앤드 우먼즈 하스피털, 인크. 섬유증의 검출 및 치료
US8545927B2 (en) 2010-05-10 2013-10-01 University Of Connecticut Lactoferrin-based biomaterials for tissue regeneration and drug delivery
AU2011254206B2 (en) 2010-05-20 2015-06-25 Ecolab Usa Inc. Rheology modified low foaming liquid antimicrobial compositions and methods of use thereof
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
EP2593141B1 (de) 2010-07-16 2018-07-04 Atrium Medical Corporation Zusammensetzung und verfahren zur veränderung der geschwindigkeit einer hydrolyse ausgehärteter materialien auf ölbasis
CA2807127C (en) 2010-08-02 2019-02-12 Leslie S. Johnson Covalent diabodies and uses thereof
PL2654785T3 (pl) 2010-12-22 2019-09-30 Bayer Intellectual Property Gmbh Wzmocniona odpowiedź immunologiczna u gatunków wołowatych
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
BR112013017943A2 (pt) 2011-01-12 2018-12-18 Array Biopharma Inc benzoazepinas substituídas como moduladores receptores do tipo toll
WO2012097177A2 (en) 2011-01-12 2012-07-19 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
EP3178932A1 (de) 2011-02-03 2017-06-14 Mirna Therapeutics, Inc. Synthetische mimetika von mir-34
MX2013008944A (es) 2011-02-03 2014-01-08 Mirna Therapeutics Inc Mimeticos sinteticos de mir-124.
US9707375B2 (en) 2011-03-14 2017-07-18 Rochester Medical Corporation, a subsidiary of C. R. Bard, Inc. Catheter grip and method
WO2012126013A2 (en) 2011-03-17 2012-09-20 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
BR112013027057A2 (pt) 2011-04-21 2020-08-11 Trustees Of Tufts College composições e métodos para a estabilização de agentes ativos
WO2012162068A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
AU2012262014B2 (en) 2011-06-01 2016-07-14 Janus Biotherapeutics, Inc. Novel immune system modulators
WO2012167053A1 (en) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
AU2012284097B2 (en) 2011-07-18 2017-08-03 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
WO2013013061A1 (en) 2011-07-19 2013-01-24 University Of Vermont And State Agricultural College Methods and compounds for treating cancer
US8726483B2 (en) 2011-07-29 2014-05-20 Abbott Cardiovascular Systems Inc. Methods for uniform crimping and deployment of a polymer scaffold
EP2739734A1 (de) 2011-08-03 2014-06-11 The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System Behandlung von fibrose mit mikrorna-19b
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
EP2744506B1 (de) 2011-08-18 2019-10-09 Upstream Medical Technologies Limited Kardiovaskuläre therapeutika
KR101494594B1 (ko) 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
CA2850932A1 (en) 2011-10-04 2013-04-11 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
CA2852244C (en) 2011-10-17 2023-10-17 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
WO2013082275A1 (en) 2011-11-30 2013-06-06 Trustees Of Boston College Inhibitors of phosphodiesterases 11 (pde11) and methods of use to elevate cortisol production
EP3050900A1 (de) 2011-12-19 2016-08-03 Xoma (Us) Llc Verfahren zur behandlung von akne
US20130158132A1 (en) * 2011-12-19 2013-06-20 Aida Salatinjants Formulation Solution Adapted To Prolong Plasma Times Of Drugs In Mammals Including Humans
WO2013106489A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
CN104582715A (zh) 2012-07-11 2015-04-29 佛蒙特大学及州农业学院 用于代谢调节的方法和组合物
SG11201500243WA (en) 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
EP2904119B1 (de) 2012-10-02 2020-06-17 The General Hospital Corporation d/b/a Massachusetts General Hospital Verfahren für mit dem dna-erfassungspfad assoziierten leiden
US9962448B2 (en) 2012-10-04 2018-05-08 Northeastern University Compounds and methods for targeted immune system delivery
US10106778B2 (en) 2012-11-08 2018-10-23 Whitehead Institute For Biomedical Research Selective targeting of cancer stem cells
US10092728B2 (en) 2012-11-20 2018-10-09 Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. Sheath for securing urinary catheter
US9872969B2 (en) 2012-11-20 2018-01-23 Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. Catheter in bag without additional packaging
US9750718B2 (en) 2012-12-12 2017-09-05 The Charlotte-Mecklenburg Hospital Authority Methods of treating hepatic fibrosis and associated diseases by regulating Rev-ERB activity
US9872851B2 (en) 2012-12-12 2018-01-23 The Charlotte-Mecklenburg Hospital Authority Methods of treating portal hypertension
WO2014100439A2 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP2935332B1 (de) 2012-12-21 2021-11-10 MedImmune, LLC Anti-h7cr antikörpern
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586790B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 음이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586789B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
CN105377355A (zh) 2013-03-14 2016-03-02 拇趾公司 治疗甲单元的感染、疾病或病症的方法
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
KR102457668B1 (ko) 2013-03-15 2022-10-21 트러스티즈 오브 터프츠 칼리지 저분자량 실크 조성물 및 안정화 실크 조성물
US11376329B2 (en) 2013-03-15 2022-07-05 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
JP6682426B2 (ja) 2013-05-24 2020-04-15 メディミューン，エルエルシー 抗ｂ７−ｈ５抗体およびその使用
JP6687520B2 (ja) 2013-07-18 2020-04-22 トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー 極めて長い相補性決定領域を有するヒト化抗体
EP3022224A2 (de) 2013-07-18 2016-05-25 Fabrus, Inc. Antikörper mit ultralangen komplementaritätsbestimmenden regionen
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2840091A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
EP2839842A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
US10286078B2 (en) 2013-09-13 2019-05-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
EP3057991B8 (de) 2013-10-15 2019-09-04 The Scripps Research Institute Chimäre antigenrezeptor-t-zell-schalter und verwendungen davon
EP3057994B1 (de) 2013-10-15 2020-09-23 The Scripps Research Institute Chimäre peptidische antigenrezeptor-t-zell-schalter und verwendungen davon
JP6306700B2 (ja) 2013-11-01 2018-04-04 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ アルブミン改変体及びその使用
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3079668A1 (de) 2013-12-09 2016-10-19 Durect Corporation Pharmazeutisch aktive wirkstoffkomplexe, polymerkomplexe und zusammensetzungen und verfahren damit
EP3083658B1 (de) 2013-12-18 2019-05-08 President and Fellows of Harvard College Detektion gram-positiver bakterien mit crp
CA2933701C (en) 2013-12-18 2022-05-31 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
EP3095460A4 (de) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chirales nukleinsäureadjuvans mit antiallergischer wirkung und antiallergikum
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
EP3104880B1 (de) 2014-02-14 2020-03-25 MacroGenics, Inc. Verbesserte verfahren zur behandlung von vaskularisierenden karzinomen
EP3110940A1 (de) 2014-02-28 2017-01-04 Bayer Animal Health GmbH Immunstimulierende plasmide
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US10398672B2 (en) 2014-04-29 2019-09-03 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
EP4331618A3 (de) 2014-05-09 2024-06-12 Yale University Hyperverzweigte polyglycerolbeschichtete partikel und verfahren zur herstellung und verwendung davon
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
TWI742423B (zh) 2014-05-29 2021-10-11 美商宏觀基因股份有限公司 特異性結合多種癌症抗原的三特異性結合分子和其使用方法
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
EP3398948A3 (de) 2014-08-22 2018-12-05 Janus Biotherapeutics, Inc. 2,4,6,7-tetrasubstituierte pteridinverbindungen und verfahren zur synthese und verwendung davon
KR102462510B1 (ko) 2014-08-26 2022-11-01 씨. 알. 바드, 인크. 요로 카테터
EA201790719A1 (ru) 2014-09-26 2017-07-31 Макродженикс, Инк. Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
WO2016057921A1 (en) 2014-10-10 2016-04-14 Baker Jr James R Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
US20160106804A1 (en) 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability
EP3206491B1 (de) 2014-10-17 2019-11-27 Salix Pharmaceuticals, Inc. Verwendung von methylnaltrexon zur verringerung der tumorprogression
EP4636401A2 (de) 2014-12-19 2025-10-22 The Broad Institute, Inc. Verfahren zur profilierung des t-zell-rezeptor-repertoirs
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
CA2976089C (en) 2015-02-10 2026-01-13 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
US9999527B2 (en) 2015-02-11 2018-06-19 Abbott Cardiovascular Systems Inc. Scaffolds having radiopaque markers
CA2977050A1 (en) 2015-02-18 2016-08-25 University Of Vermont And State Agricultural College Mcj agonists and uses therefor
EP4226937A3 (de) 2015-03-05 2023-09-27 Northwestern University Nichtneuroinvasive viren und verwendungen davon
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
EP3283127B1 (de) 2015-04-15 2020-02-26 University of Massachusetts Zusammensetzungen und verfahren zur reaktivierung chromosom xi
EP3283113A4 (de) 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimierte pne-basierte chimäre t-zell-rezeptor-schalter und verwendungen davon
MX2017014700A (es) 2015-05-20 2018-08-15 Broad Inst Inc Neoantigenos compartidos.
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
US9700443B2 (en) 2015-06-12 2017-07-11 Abbott Cardiovascular Systems Inc. Methods for attaching a radiopaque marker to a scaffold
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
EP3319636A2 (de) 2015-07-10 2018-05-16 University of Vermont and State Agricultural College Mcj-inhibitoren zur behandlung von medikamenteninduzierten krankheiten und leiden
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
HUE055207T2 (hu) 2015-07-30 2021-11-29 Macrogenics Inc PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására
EP3763378A1 (de) 2015-08-06 2021-01-13 President and Fellows of Harvard College Verbesserte mikrobenbindende moleküle und verwendungen davon
WO2017029556A1 (en) 2015-08-20 2017-02-23 Asociación Centro De Investigación Cooperativa En Biociencias - Cis Biogune Methods and compositions to treat liver diseases and conditions
JP2018528968A (ja) 2015-09-17 2018-10-04 ユニバーシティ オブ マサチューセッツ Ｆｍｒ１発現を調節するための組成物および方法
CN114470194A (zh) 2015-12-02 2022-05-13 斯特库伯株式会社 与btn1a1免疫特异性结合的抗体和分子及其治疗用途
US11253590B2 (en) 2015-12-02 2022-02-22 Stsciences, Inc. Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
EA201891178A1 (ru) 2015-12-14 2019-01-31 Макродженикс, Инк. Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
AU2017221424A1 (en) 2016-02-16 2018-09-20 Yale University Compositions and methods for treatment of cystic fibrosis
EP3416976A2 (de) 2016-02-16 2018-12-26 Yale University Zusammensetzungen zur verbesserung von gezielter geneditierung und verfahren zur verwendung davon
WO2017173334A1 (en) 2016-04-01 2017-10-05 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017177199A2 (en) 2016-04-08 2017-10-12 Iti Health, Inc. Plectin-1 binding antibodies and uses thereof
TWI781098B (zh) 2016-04-15 2022-10-21 美商宏觀基因股份有限公司 新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
EP3454891A4 (de) 2016-05-10 2019-12-25 The Regents of The University of Michigan Emulsionsadjuvans zur intramuskulären, intradermalen und subkutanen verabreichung
WO2017207623A1 (en) 2016-05-31 2017-12-07 Université de Lausanne Mirna as biomarkers and regulators of cancer stem cells
US20190322643A1 (en) 2016-06-29 2019-10-24 Georgia State University Research Foundation, Inc. Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
SG11201811760VA (en) 2016-07-06 2019-01-30 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer
US10933131B2 (en) 2016-07-26 2021-03-02 Bayer Animal Health Gmbh Increased fertility in bovine species
US9980850B2 (en) 2016-09-29 2018-05-29 Gesea Biosciences, Inc. Bioerodible contraceptive implant and methods of use thereof
US20210007973A1 (en) * 2016-10-05 2021-01-14 Titan Pharmaceuticals, Inc. Implantable devices for drug delivery with reduced burst release
WO2018075807A1 (en) 2016-10-19 2018-04-26 California Institute For Biomedical Research Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
WO2018085842A1 (en) 2016-11-07 2018-05-11 University Of Massachusetts Therapeutic targets for facioscapulohumeral muscular dystrophy
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2018145109A1 (en) 2017-02-06 2018-08-09 Massachusetts Institute Of Technology Methods and products related to glutaminase inhibitors
US20200113821A1 (en) 2017-04-04 2020-04-16 Yale University Compositions and methods for in utero delivery
US11225512B2 (en) 2017-04-27 2022-01-18 University Of New Hampshire Compositions and methods for ceramide-elevating therapeutic strategies
EP3630834A1 (de) 2017-05-31 2020-04-08 STCube & Co., Inc. Verfahren zur behandlung von krebs mit antikörpern und molekülen, die immunspezifisch an btn1a1 binden
WO2018222689A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
CN121609797A (zh) 2017-06-06 2026-03-06 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
EP3651750A4 (de) 2017-07-14 2021-04-14 University of Massachusetts Verfahren und zusammensetzungen zur behandlung von entzündungen
EP3678698A1 (de) 2017-09-07 2020-07-15 University Of Oslo Impfstoffmoleküle
US12005112B2 (en) 2017-09-07 2024-06-11 University Of Oslo Vaccine molecules
JP7350722B2 (ja) 2017-09-19 2023-09-26 シー・アール・バード・インコーポレーテッド 尿カテーテルブリッジ装置、そのシステムおよび方法
MX2020006188A (es) 2017-12-18 2020-09-17 Foresee Pharmaceuticals Co Ltd Composiciones farmaceuticas que tienen una duracion de liberacion seleccionada.
WO2019154884A1 (en) 2018-02-07 2019-08-15 Ecole Polytechnique Federale De Lausanne (Epfl) Method for determining cancer invasiveness and patient prognosis
US12246031B2 (en) 2018-02-13 2025-03-11 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
MX2020010410A (es) 2018-04-09 2021-01-15 Checkmate Pharmaceuticals Empaquetado de oligonucleotidos en particulas similares a virus.
PL3773537T3 (pl) 2018-04-19 2022-05-23 Tvardi Therapeutics, Inc. Inhibitory stat3
CA3103265A1 (en) 2018-06-12 2019-12-19 Angiex, Inc. Antibody-oligonucleotide conjugates
CA3110250A1 (en) 2018-08-22 2020-02-27 Bacainn Therapeutics, Ltd. Cyclosporine compositions and methods of use
CN109289089B (zh) * 2018-10-15 2021-12-28 福建师范大学 基于二氧化钛纳米管阵列的温控智能释药系统的制备方法
CN109289049B (zh) * 2018-10-15 2021-04-02 福建师范大学 基于二氧化钛纳米管阵列的近红外光控智能释药系统的制备方法
EP3867365A1 (de) 2018-10-19 2021-08-25 Board of Regents, The University of Texas System Gentechnisch hergestellte transposons mit langem interspergiertem element (line) und verwendungsverfahren dafür
CN113557008A (zh) 2018-10-29 2021-10-26 弗劳恩霍夫应用研究促进协会 具有持续活性的四环素类络合物
MX2021005967A (es) 2018-11-21 2021-10-13 Tremeau Pharmaceuticals Inc Formas purificadas de rofecoxib, métodos de fabricación y uso.
EP3677693A1 (de) 2019-01-03 2020-07-08 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Transpochimäre gentranskripte (tcgts) als krebsbiomarker
JP2022527569A (ja) 2019-03-21 2022-06-02 ミトセラピューティクス・エルエルシー 治療剤の標的化送達のための多価リガンドクラスター
WO2020257779A1 (en) 2019-06-21 2020-12-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
US20220243211A1 (en) 2019-06-21 2022-08-04 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
WO2021022161A1 (en) 2019-07-31 2021-02-04 Yale University Compositions and methods for treating sickle cell disease
US12098212B2 (en) 2019-08-12 2024-09-24 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
EP4041767A1 (de) 2019-09-26 2022-08-17 StCube & Co. Spezifische antikörper gegen glykosiertes ctla-4 und verfahren zur verwendung davon
CN114828963A (zh) 2019-10-07 2022-07-29 D·E·萧尔研究有限责任公司 作为Kv1.3钾SHAKER通道阻滞剂的芳基杂二环化合物
CR20220148A (es) 2019-10-07 2022-07-03 De Shaw Res Llc Compuestos heterocíclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3
KR20220088438A (ko) 2019-10-09 2022-06-27 주식회사 에스티큐브앤컴퍼니 글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
US20220380487A1 (en) 2019-10-24 2022-12-01 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
EP4090353A4 (de) 2020-01-13 2023-08-09 Durect Corporation Arzneimittelabgabesysteme mit verzögerter freisetzung mit reduzierten verunreinigungen und verwandte verfahren
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
WO2021168373A1 (en) 2020-02-21 2021-08-26 Mitotherapeutix Llc Compositions and methods for inhibiting expression of methylation-controlled j-protein (mcj)
EP4146667A4 (de) 2020-05-08 2024-06-19 Georgiamune Inc. Akt3-modulatoren
AU2021299156C1 (en) 2020-06-30 2025-02-06 Chong Kun Dang Pharmaceutical Corp. Injectable composition comprising GnRH analogue
CA3193554A1 (en) 2020-10-06 2022-04-14 D.E. Shaw Research, Llc Lactam compounds as kv1.3 potassium shaker channel blockers
JP2024503402A (ja) 2021-01-12 2024-01-25 デュレクト コーポレーション 徐放性薬物送達システム及び関連の方法
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof
CN118251420A (zh) 2021-04-28 2024-06-25 米诺陶治疗公司 人源化嵌合牛抗体和使用方法
WO2022237974A1 (en) 2021-05-12 2022-11-17 Ecole Polytechnique Federale De Lausanne (Epfl) Krab-containing zinc finger protein and cancer
CR20230555A (es) 2021-05-28 2024-02-19 De Shaw Res Llc Compuestos de espiroindolinona como bloqueadores del canal agitador de potasio kv1.3
EP4352226A1 (de) 2021-06-07 2024-04-17 Yale University Peptidnukleinsäuren zur räumlich-zeitlichen steuerung der crispr-cas-bindung
CN117794946A (zh) 2021-06-09 2024-03-29 斯克利普斯研究所 长效双重gip/glp-1肽缀合物及使用方法
AU2022202053A1 (en) 2021-09-17 2023-04-06 Biocorrx, Inc. Biodegradable implant including naltrexone
WO2023056368A1 (en) 2021-09-30 2023-04-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cyclic peptides as non-hormonal male contraceptive agents and methods of use thereof
MX2024005862A (es) 2021-11-16 2024-07-10 Shanghai Argo Biopharmaceutical Co Ltd Composiciones y metodos para inhibir la expresion de la proteina angiotensinogeno (agt).
CN117043338A (zh) 2021-11-29 2023-11-10 上海舶望制药有限公司 用于抑制乙型肝炎病毒(hbv)蛋白表达的组合物和方法
TW202345865A (zh) 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
WO2023148398A1 (en) 2022-02-07 2023-08-10 Var2 Pharmaceuticals Aps Antibodies and antibody fragments and analogues specific for chondroitin sulfate
EP4514389A1 (de) 2022-04-29 2025-03-05 Purinomia Biotech, Inc. Verfahren und zusammensetzungen zur behandlung von eosinophil-bedingten erkrankungen und störungen
JP2025527492A (ja) 2022-08-18 2025-08-22 エランコ・ユーエス・インコーポレイテッド 肥育素牛の発育成績を改善する方法
AU2023404700A1 (en) 2022-12-02 2025-07-10 Shanghai Argo Biopharmaceutical Co., Ltd. Bicyclic abasic nucleic acid analogs and oligomeric compounds prepared therefrom
TW202444908A (zh) 2023-04-06 2024-11-16 大陸商上海舶望製藥有限公司 ５＇－膦酸酯修飾的核苷類似物及其製備的寡核苷酸
WO2024263649A1 (en) 2023-06-19 2024-12-26 Yale University Methods and compositions for enrichment and sequencing of expansion-specific rna transcripts
WO2025029769A1 (en) 2023-07-31 2025-02-06 Eli Lilly And Company Solid forms of a kv1.3 potassium shaker channel blockers and method of using the same
WO2025247961A1 (en) 2024-05-31 2025-12-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Lpa-lpar signaling as a therapeutic target or diagnostic tool for brain diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4148871A (en) * 1977-10-11 1979-04-10 Pitt Colin G Sustained subdermal delivery ofdrugs using poly(ε-caprolactone) and its copolymers
US4292965A (en) * 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
US4341728A (en) * 1979-12-20 1982-07-27 The Population Council, Inc. Method for making an IUD with shrinking of a medicated attachment onto a support
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) * 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4906474A (en) * 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
IL73327A (en) * 1984-10-26 1988-03-31 Tzora Furniture Ind Ltd Infants amusement device
US4702917A (en) * 1985-11-18 1987-10-27 Research Triangle Institute Porous bioabsorbable polyesters
WO1988007816A1 (en) * 1987-04-06 1988-10-20 Endocon, Inc. Flash flow fused medicinal implants
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5324520A (en) * 1988-12-19 1994-06-28 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
US5077049A (en) * 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
US5487897A (en) * 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
WO1992000718A1 (en) * 1990-07-03 1992-01-23 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
EP0523330B1 (de) * 1991-06-24 1996-03-20 American Cyanamid Company Implantationzusammensetzungen, die biologisch aktive Proteine, Peptide oder Polypeptide enthalten
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
EP0560014A1 (de) * 1992-03-12 1993-09-15 Atrix Laboratories, Inc. Biologisch abbaubarer Wundverband in Form eines Sprühfilms und Verfahren zu seiner Herstellung
DK0754032T3 (da) * 1994-04-08 2002-04-02 Atrix Lab Inc Flydende frigivelsessammensætninger
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system

Also Published As

Publication number Publication date
US5736152A (en) 1998-04-07
JP2009019038A (ja) 2009-01-29
AU7665096A (en) 1997-05-15
WO1997015285A1 (en) 1997-05-01
DK0862416T3 (da) 2003-02-03
EP0862416A1 (de) 1998-09-09
ES2184895T3 (es) 2003-04-16
US6120789A (en) 2000-09-19
CA2235919C (en) 2005-09-13
US5888533A (en) 1999-03-30
DE69623981T2 (de) 2003-08-07
JP2001508756A (ja) 2001-07-03
JP4599498B2 (ja) 2010-12-15
EP0862416B1 (de) 2002-09-25
AU703365B2 (en) 1999-03-25
DE69623981D1 (de) 2002-10-31
CA2235919A1 (en) 1997-05-01

Similar Documents

Publication Publication Date Title
ATE224702T1 (de) Nichtpolymere verabreichungssysteme mit verzögerter freisetzung
JP5004295B2 (ja) 口内薬物送達のためのシステムおよび方法
DE59610355D1 (de) Medizinisches implantat
WO2005034852A3 (en) Protein biomaterials and biocoacervates and methods of making and using thereof
FI952701A0 (fi) Metallisen kirurgisen istukkaan käsittelymenetelmä
EP1272249A4 (de) Kathetersystem zum einbringen eines implantats sowie anwendungsverfahren dafür
DE50210591D1 (de) Implantate mit fk506 zur restenosebehandlung und -prophylaxe
ATE515995T1 (de) Vorrichtung zur freigabe von bioaktiven substanzen und verfahren zu deren herstellung
EP1982695A3 (de) Herstellung von Vorrichtungen zur Langzeitarzneimittelversorgung mit Polyurethan
DE60330144D1 (de) Beschichtung von stents mit verzögerter wirkstofffreisetzung
HUP0102899A2 (hu) Eljárás gyulladásgátló, különösen fertőtlenítő hatású és/vagy sebgyógyulást elősegítő szerek alsó légutakba történő beadására szolgáló készítmények előállítására
CA2158638A1 (en) A Composition and a Method for Tissue Augmentation
ATE286384T1 (de) Formulierung mit verzögerter freisetzung enthaltend kollagen und glykosaminoglykan
MX2007002688A (es) Dispositivo para administrar agentes bioactivos y metodo de fabricacion.
MXPA03010402A (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina.
CY1105634T1 (el) Η χρηση του ραδιου -223 για τη στοχευση ασβεστωμενων ιστων για την ανακουφιση πονου και τη θεραπεια οστικου καρκινου
IT1307829B1 (it) Protesi dentale con mezzi per il rilascio di farmaci o fattorispecifici atti ad impedire l'insorgenza di infezioni e/o promuovere
IL122248A (en) Use of nisin in the manufacture of a medicament for the treatment of an infection and pharmaceutical compositions comprising nisin for said treatment
ATE316779T1 (de) Implantate zur gesteuerten freisetzung von pharmazeutischen wirkstoffen und verfahren zur herstellung
US5814331A (en) Process for inhibiting pathogenic bacteria in the oral cavity and for binding peptide growth factors on surfaces
DE69426530D1 (de) Pharmazeutische zusammensetzung zur förderung der gewebeheilung und -regenerierung und darreichungssatz
ATE308973T1 (de) Heparin-stent
ATE458471T1 (de) Formulierungen mit povidon-iod zur behandlung von wunden
CN1228145C (zh) 用高效材料涂布物件的装置、方法及其应用和成品
DE60231785D1 (de) Gelierbare, biokompatible und implantierbare zusammensetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0862416

Country of ref document: EP